X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3387) 3387
Newsletter (75) 75
Newspaper Article (40) 40
Book Chapter (15) 15
Magazine Article (13) 13
Dissertation (9) 9
Publication (5) 5
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Streaming Video (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sitagliptin (2639) 2639
humans (1772) 1772
diabetes mellitus, type 2 - drug therapy (1312) 1312
type 2 diabetes (1246) 1246
male (1222) 1222
endocrinology & metabolism (989) 989
diabetes (977) 977
female (970) 970
middle aged (853) 853
hypoglycemic agents - therapeutic use (852) 852
sitagliptin phosphate (841) 841
metformin (746) 746
aged (641) 641
dipeptidyl-peptidase iv inhibitors - therapeutic use (624) 624
glucose (560) 560
animals (534) 534
pharmacology & pharmacy (532) 532
safety (515) 515
treatment outcome (512) 512
glycemic control (509) 509
dipeptidyl peptidase-4 inhibitor (498) 498
efficacy (493) 493
glucagon-like peptide-1 (493) 493
diabetes mellitus (485) 485
double-blind (482) 482
diabetes mellitus, type 2 - blood (462) 462
insulin (460) 460
adult (456) 456
hypoglycemic agents (448) 448
pyrazines - therapeutic use (438) 438
triazoles - therapeutic use (438) 438
hypoglycemic agents - adverse effects (415) 415
research (410) 410
care and treatment (397) 397
hypoglycemic agents - administration & dosage (367) 367
diabetes therapy (366) 366
drug therapy, combination (361) 361
vildagliptin (358) 358
dipeptidyl-peptidase iv inhibitors - pharmacology (351) 351
analysis (347) 347
drug therapy (345) 345
blood glucose - metabolism (344) 344
type 2 diabetes mellitus (330) 330
blood glucose - drug effects (329) 329
liraglutide (309) 309
medicine, general & internal (301) 301
sitagliptin phosphate - therapeutic use (286) 286
dipeptidyl-peptidase iv inhibitors - adverse effects (285) 285
exenatide (284) 284
clinical trials (279) 279
risk factors (273) 273
mellitus (269) 269
double-blind method (268) 268
metformin - therapeutic use (267) 267
glycated hemoglobin a - metabolism (259) 259
dosage and administration (258) 258
internal medicine (256) 256
hypoglycemic agents - pharmacology (255) 255
dextrose (243) 243
monotherapy (243) 243
rats (242) 242
dpp-4 inhibitor (239) 239
therapy (234) 234
dipeptidyl peptidase-4 inhibitors (233) 233
triazoles - pharmacology (233) 233
pyrazines - pharmacology (230) 230
glucagon (228) 228
hypoglycemia (227) 227
diabetes mellitus, type 2 - complications (223) 223
adamantane - analogs & derivatives (220) 220
mice (220) 220
saxagliptin (220) 220
type-2 diabetes-mellitus (215) 215
hyperglycemia (213) 213
dipeptidyl-peptidase iv inhibitors - administration & dosage (211) 211
glp-1 (206) 206
triazoles - administration & dosage (204) 204
pyrazines - administration & dosage (203) 203
beta-cell function (202) 202
risk (202) 202
insulin resistance (199) 199
dipeptidyl peptidase 4 - metabolism (197) 197
medicine, research & experimental (195) 195
glycosylated hemoglobin (188) 188
patients (187) 187
pyrazines - adverse effects (185) 185
medicine & public health (183) 183
triazoles - adverse effects (183) 183
peptidase (180) 180
medical research (179) 179
health aspects (178) 178
linagliptin (174) 174
body weight (168) 168
studies (167) 167
glycated hemoglobin a - analysis (164) 164
cardiac & cardiovascular systems (162) 162
peptides (162) 162
inflammation (160) 160
pharmacokinetics (160) 160
dpp-4 inhibitors (159) 159
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3361) 3361
German (53) 53
Japanese (35) 35
French (29) 29
Spanish (18) 18
Hungarian (15) 15
Korean (14) 14
Russian (14) 14
Chinese (11) 11
Czech (11) 11
Portuguese (8) 8
Dutch (3) 3
Italian (3) 3
Swedish (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
Diabetes care, ISSN 1935-5548, 2014, Volume 37, Issue 8, pp. 2149 - 2158
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2019, Volume 321, Issue 15, pp. 1466 - 1480
Journal Article
Diabetes care, ISSN 1935-5548, 2016, Volume 39, Issue 12, pp. 2304 - 2310
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 378 - 388
Aims To assess the safety and efficacy of monotherapy with once‐weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes... 
GLP‐1 | sitagliptin | type 2 diabetes | GLP-1 | METFORMIN | ADD-ON | AMERICAN ASSOCIATION | HUMAN GLP-1 ANALOG | EXENATIDE | PHASE 3A | OPEN-LABEL | CLINICAL ENDOCRINOLOGISTS | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | ACUTE-PANCREATITIS | Glycated Hemoglobin A - analysis | Follow-Up Studies | Nausea - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diarrhea - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glucagon-Like Peptides - administration & dosage | Humans | Nausea - physiopathology | Patient Dropouts | Weight Loss - drug effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Nausea - therapy | Injections, Subcutaneous | Hypoglycemia - chemically induced | Severity of Illness Index | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Drug Administration Schedule | Administration, Oral | Japan | Constipation - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Constipation - chemically induced | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diarrhea - therapy | Constipation - therapy | Incretins - adverse effects | Sitagliptin Phosphate - therapeutic use | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Diabetes mellitus | Body weight | Hemoglobin | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Original
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2016, Volume 39, Issue 3, pp. 455 - 464
Journal Article
British journal of pharmacology, ISSN 0007-1188, 2017, Volume 174, Issue 14, pp. 2273 - 2286
Background and Purpose Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia–reperfusion injury (IRI) are... 
ACUTE KIDNEY INJURY | ISCHEMIA/REPERFUSION INJURY | ANIMAL RESEARCH | OSTEOPONTIN | SITAGLIPTIN | ALPHA CELLS | RATS | PHARMACOLOGY & PHARMACY | FACTOR-I | UP-REGULATION | ARRIVE GUIDELINES | Dipeptidyl Peptidase 4 - metabolism | Linagliptin - administration & dosage | Sitagliptin Phosphate - pharmacology | Kidney - pathology | Nitriles - pharmacology | Rats, Wistar | Reperfusion Injury - drug therapy | Pyrrolidines - administration & dosage | Male | Sitagliptin Phosphate - chemistry | Structure-Activity Relationship | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Kidney - metabolism | Molecular Structure | Adamantane - administration & dosage | Reperfusion Injury - metabolism | Adamantane - analogs & derivatives | Linagliptin - pharmacology | Sitagliptin Phosphate - administration & dosage | Adamantane - pharmacology | Kidney - drug effects | Reperfusion Injury - pathology | Rats | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Pyrrolidines - chemistry | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Linagliptin - chemistry | Animals | Nitriles - chemistry | Vildagliptin | Adamantane - chemistry | Comparative analysis | Reperfusion injury | Cystatin | Damage assessment | Peptidase | Renal artery | Glucagon | Osteopontin | Biomedical materials | Inhibitors | Reperfusion | Ischemia | Rodents | Cystatin C | Biocompatibility | Plasma levels | Mathematical models | Inhibition | Research Papers | Research Paper
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TO-TARGET TRIAL | BEGIN | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Complications | Research
Journal Article
Journal Article